News for Precision BioSciences, Inc. (DTIL)

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene edit

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene edit

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Shares of Precision BioSciences, Inc. DTIL rose sharply in today's pre-market trading. Precision BioSciences reported clearance of investigational new drug app...

**media[555305]**

Precision BioSciences (NASDAQ:DTIL) stock gains as company reports promising Phase 1 trial results for its Hepatitis B gene therapy, PBGENE-HBV. Read more here.

On December 31, 2024, Aquilo Capital Management, LLC (Trades, Portfolio) made a significant move by acquiring an additional 410,059 shares of Precision BioScien

Overview of the Recent Transaction On December 31, 2024, Lynx1 Capital Management LP (Trades, Portfolio) executed a notable transaction by acquiring 766,051 sha

**media[538355]**

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERTâ„¢ platform to support the development and commercialization of azer-cel, its all

Precision Biosciences CEO sells $172,033 in stock

Precision BioSciences (DTIL) stock saw a 31% premarket surge after positive results from its gene therapy trial for treating OTC deficiency. Read more here.

Shares of Zoomcar Holdings Inc ZCAR rose sharply in today's pre-market trading after the company announced a significant achievement in its financial performanc...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene edit

On December 30, 2024, Geno Germano, Director at Precision BioSciences Inc (DTIL), purchased 3,605 shares of the company. Following this transaction, the insider

Precision BioSciences stock hits 52-week low at $4.12

Precision Biosciences CFO buys $10,036 in common stock

Precision BioSciences stock hits 52-week low at $6.4

Precision BioSciences stock hits 52-week low at $7.94